RxDoctor Payments Data

Jefferson Gordon, MD

Family Medicine · Carrollton, GANPI 1336167816

Payments from drug & device makers

$7,691in general payments, 2019–2025

Across 469 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$898
  • Pfizer$632
  • Lilly USA, LLC$623
  • Astellas Pharma US Inc$622
  • Amgen$585
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$7,57899%
  • Education$991%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,691 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$207,618
Medicare patients
480
Services billed
7,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon12$290,932
EliquisApixaban192$145,273
FarxigaDapagliflozin Propanediol59$40,223
JardianceEmpagliflozin47$38,014
OzempicSemaglutide28$28,443
XareltoRivaroxaban31$24,360
JanuviaSitagliptin Phosphate13$20,870
MounjaroTirzepatide17$18,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,793
MyrbetriqMirabegron20$11,865
EntrestoSacubitril/Valsartan11$11,577
TradjentaLinagliptin15$11,536
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,393
Levothyroxine Sodium524$5,663
Atorvastatin Calcium567$4,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$22$290,93212 claims
PfizerEliquis$632$145,273192 claims
Boehringer IngelheimJardiance, Tradjenta$194$49,55062 claims
AstraZenecaFarxiga$257$40,22359 claims
Novo NordiskOzempic$898$28,44328 claims
Johnson & JohnsonXarelto$299$24,36031 claims
GSKTrelegy Ellipta, Anoro Ellipta$421$22,18630 claims
MerckJanuvia$42$20,87013 claims
Lilly USA, LLCMounjaro$623$18,29317 claims
Astellas Pharma US IncMyrbetriq$622$11,86520 claims
NovartisEntresto$90$11,57711 claims
AbbVieSynthroid$1,202$2,11932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →